AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04542746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical technique
Description: After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
Study NCT04919785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
Study NCT02270697 — intervention group
Intervention type: DEVICE
Intervention: Array
Description: Applications of oligonucleotide array in diagnosis.
Study NCT00227370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valganciclovir
Description: valgan 900mg QD x 9 months post lung transplant
Study NCT00227370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03056144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration therapy
Description: The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~1. st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~2. nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~3. th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~4. th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min >5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant.
Study NCT03332732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5133
Description: β-lactamase inhibitor
Study NCT03332732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5022
Description: Approved β-lactam antibiotic
Study NCT03332732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Approved antibiotic and antiprotozoal medication
Study NCT03332732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (matching VNRX-5133 + VNRX-5022)
Study NCT02291796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
Study NCT01739647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: Oral solution
Study NCT01739647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study NCT01670643 — intervention group
Intervention type: BEHAVIORAL
Intervention: Video camera magnifier
Description: reading with video camera magnifier
Study NCT04254133 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Complete questionnaire
Study NCT04254133 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Provide saliva samples
Study NCT04254133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: Undergo genetic testing
Study NCT04254133 — intervention group
Intervention type: OTHER
Intervention: Genetic Counseling
Description: Undergo counseling
Study NCT04254133 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT04444063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Incised Papilla Surgical Approach
Description: Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture.
Study NCT04444063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Incised Papilla Surgical Approach
Description: Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture.
Study NCT04094610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral repotrectinib (TPX-0005)
Description: Oral repotrectinib (TPX-0005)
Study NCT01220154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
Study NCT01220154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intraperitoneal Day 1 cycles 1-6 AUC
Study NCT01933789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Feedback Form for Patients with Serious Illness
Description: The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately.
Study NCT02757950 — intervention group
Intervention type: BIOLOGICAL
Intervention: Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]
Description: Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
Study NCT00623584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal transplantation
Description: Full thickness penetrating keratoplasty
Study NCT00623584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal transplantation
Description: Full thickness penetrating keratoplasty
Study NCT00167466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soladey-3 toothbrush
Description: subject to brush with experimental Soladey-3 brush for 4 week
Study NCT00167466 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Soladey-3 toothbrush
Description: subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
Study NCT02710643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFATUMUMAB
Description: 8 weekly infusion of 1000 mg total dose
Study NCT05719987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: After the endodontic procedure, Biodentine will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
Study NCT05719987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MTA
Description: After the endodontic procedure, MTA will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
Study NCT01235871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB1578
Description: JAK2 Inhibitor
Study NCT01235871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study NCT02633852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Study NCT03809793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: 12-week walking based intervention (3 sessions per week)
Study NCT03809793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: 12-week walking based intervention (3 sessions per week)
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DXA
Description: Participants will undergo an assessment of body composition (DXA)
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: DXA
Description: Participants will undergo an assessment of body composition (DXA)
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: used to measure fat stored in the liver
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: used to measure fat stored in the liver
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinaemic Euglycaemic Clamp
Description: Participants will arrive at the laboratory after an overnight fast (>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hyperinsulinaemic Euglycaemic Clamp
Description: Participants will arrive at the laboratory after an overnight fast (>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
Study NCT03809793 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VO2 Max
Description: Assessment of maximum aerobic capacity.
Study NCT01667315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0,375%
Description: Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
Study NCT04201496 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
Description: Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks.
Study NCT01220154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
Study NCT04201496 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Description: Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks.
Study NCT04201496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
Description: Participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Empaglizflozin will not be provided to this group.
Study NCT04201496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Description: Participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Empaglizflozin will not be provided to this group.
Study NCT01687231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-neutropenic Diet
Description: Non-neutropenic diet is without restriction.
Study NCT00336492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
Study NCT00336492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
Study NCT00336492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
Study NCT00336492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
Study NCT02340104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4 milligrams (mg) administered orally
Study NCT02340104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^13C4D3^15N]-baricitinib
Description: 4 micrograms (μg) administered intravenously (IV)
Study NCT00915902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acid ethyl esters
Description: Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
Study NCT00915902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
Study NCT01033396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: PF-03654764 single dose 5 mg
Study NCT01033396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allegra
Description: Fexofenadine single dose 60 mg
Study NCT01033396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra-D
Description: Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
Study NCT03321617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
Study NCT01033396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose
Study NCT02688010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise reduction and cycled light
Description: Reduced noise exposure (sound levels \<45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
Study NCT04635501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABS 5.6.7
Description: Patients whose access site will be closed with the ABS 5.6.7
Study NCT02818075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Phone Based Peer Support
Description: Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
Study NCT02818075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
Study NCT02818075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
Study NCT02080130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
Study NCT04089124 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery of zone II cut flexor repair
Description: we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture
Study NCT01267435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cruciate ligament reconstruction
Description: reconstruct the anterior cruciate ligament rupturing
Study NCT01569204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT00985439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Test (lower dose)
Description: 18-mg Single dose
Study NCT00985439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Test (upper dose)
Description: 35-mg Single dose
Study NCT00985439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 400 mg
Description: Capsules 2 x 200 mg Single-dose
Study NCT00985439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules 2 Single-dose
Study NCT01929486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
Study NCT02294981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer laser phototherapy
Description: Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
Study NCT02294981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser phototherapy
Description: Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
Study NCT01152645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Orally twice daily administration of ARQ 197